Macquarie Group Ltd. Has $834,000 Holdings in MiMedx Group, Inc. (MDXG)

Macquarie Group Ltd. reduced its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 96.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 66,113 shares of the medical equipment provider’s stock after selling 1,681,996 shares during the quarter. Macquarie Group Ltd. owned 0.06% of MiMedx Group worth $834,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in MDXG. New York State Common Retirement Fund increased its stake in MiMedx Group by 42.9% during the 3rd quarter. New York State Common Retirement Fund now owns 186,929 shares of the medical equipment provider’s stock valued at $2,221,000 after purchasing an additional 56,124 shares in the last quarter. Rhumbline Advisers increased its stake in MiMedx Group by 3.0% during the 3rd quarter. Rhumbline Advisers now owns 204,587 shares of the medical equipment provider’s stock valued at $2,430,000 after purchasing an additional 6,045 shares in the last quarter. Bank of New York Mellon Corp increased its stake in MiMedx Group by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,356,635 shares of the medical equipment provider’s stock valued at $16,117,000 after purchasing an additional 10,103 shares in the last quarter. SG Americas Securities LLC increased its stake in MiMedx Group by 32.6% during the 3rd quarter. SG Americas Securities LLC now owns 44,606 shares of the medical equipment provider’s stock valued at $530,000 after purchasing an additional 10,963 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in MiMedx Group by 4.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 686,716 shares of the medical equipment provider’s stock valued at $8,158,000 after purchasing an additional 27,618 shares in the last quarter. Institutional investors and hedge funds own 80.35% of the company’s stock.

A number of analysts have weighed in on MDXG shares. BidaskClub lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Craig Hallum restated a “buy” rating on shares of MiMedx Group in a research note on Tuesday, February 27th. Needham & Company LLC lowered shares of MiMedx Group from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Lake Street Capital lowered shares of MiMedx Group from a “buy” rating to a “hold” rating and set a $9.00 price objective for the company. in a research note on Friday, February 23rd. Finally, ValuEngine lowered shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $14.75.

Shares of MDXG stock opened at $6.46 on Monday. MiMedx Group, Inc. has a 52 week low of $6.05 and a 52 week high of $18.25. The company has a market capitalization of $717.29, a PE ratio of 53.83, a P/E/G ratio of 0.84 and a beta of 1.62.

MiMedx Group announced that its Board of Directors has approved a share repurchase program on Wednesday, December 13th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical equipment provider to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/09/macquarie-group-ltd-has-834000-holdings-in-mimedx-group-inc-mdxg.html.

MiMedx Group Company Profile

MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply